\begin{tabular}{llll}
\toprule
section & characteristic & durvalumab & atezolizumab \\
\midrule
Overall & Number of reports & 6,139 & 8,750 \\
Overall & Age, median (IQR), years & 68.0 (61.0-74.0) & 68.0 (61.0-74.0) \\
Sex & Female & 1,579 (25.7) & 2,475 (28.3) \\
Sex & Male & 3,762 (61.3) & 5,183 (59.2) \\
Sex & Unknown & 798 (13.0) & 1,092 (12.5) \\
Age group & <18 & 2 (0.0) & 2 (0.0) \\
Age group & 18-44 & 85 (1.4) & 195 (2.2) \\
Age group & 45-64 & 1,446 (23.6) & 2,400 (27.4) \\
Age group & 65-74 & 1,870 (30.5) & 2,795 (31.9) \\
Age group & 75+ & 984 (16.0) & 1,664 (19.0) \\
Age group & Unknown & 1,752 (28.5) & 1,694 (19.4) \\
Reporter type & Health professional & 56 (0.9) & 37 (0.4) \\
Reporter type & Other/Unknown & 3 (0.0) & 3 (0.0) \\
Reporter type & Unknown & 6,080 (99.0) & 8,710 (99.5) \\
Lung cancer subgroup & SCLC & 5,211 (84.9) & 6,639 (75.9) \\
Lung cancer subgroup & Other/unspecified lung cancer & 928 (15.1) & 2,111 (24.1) \\
Treatment context & Monotherapy-like & 4,974 (81.0) & 4,989 (57.0) \\
Treatment context & Combination/multi-suspect & 1,165 (19.0) & 3,761 (43.0) \\
\bottomrule
\end{tabular}
